BioLeaders, Phase 2 Clinical Trial of BLS-H01 in Moderate COVID-19 Patients
[Asia Economy Reporter Minji Lee] BioLeaders announced on the 20th that it has applied to the Ministry of Food and Drug Safety for a Phase 2 clinical trial, which is a multicenter, randomized study to evaluate the efficacy and safety of BLS-H01 (poly-gamma-glutamic acid) in patients with moderate COVID-19.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "This is to comparatively evaluate the efficacy and safety of BLS-H01 administration versus placebo in patients with moderate COVID-19," adding, "Unlike other treatments, BLS-H01 stimulates TLR4 present on the cell surface, promoting the secretion of IFN-β through signal transduction, thereby activating immune cells, producing antiviral proteins that inhibit viral replication, and inducing apoptosis in virus-infected cells."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
